Session

IBD drug efficacy and safety

INTRAVENOUS ADMINISTRATION OF FLUORESCENTLY LABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCAL DRUG DISTRIBUTION AND PHARMACODYNAMICS IN INFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY
INTRAVENOUS ADMINISTRATION OF FLUORESCENTLY LABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCAL DRUG DISTRIBUTION AND PHARMACODYNAMICS IN INFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY

RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION

EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY
EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

IBD drug efficacy and safety  et al.

EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY
EFFICACY AND SAFETY OF ELECTIVE SWITCHING OF INFLAMMATORY BOWEL DISEASE PATIENTS FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB: A MULTI-CENTRE COHORT STUDY

IBD drug efficacy and safety  et al.

EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION

IBD drug efficacy and safety  et al.

RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

IBD drug efficacy and safety  et al.

INTRAVENOUS ADMINISTRATION OF FLUORESCENTLY LABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCAL DRUG DISTRIBUTION AND PHARMACODYNAMICS IN INFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY
INTRAVENOUS ADMINISTRATION OF FLUORESCENTLY LABELLED VEDOLIZUMAB TO GAIN INSIGHT IN LOCAL DRUG DISTRIBUTION AND PHARMACODYNAMICS IN INFLAMMATORY BOWEL DISEASE DURING ENDOSCOPY

IBD drug efficacy and safety  et al.

Item 1 - 10 / 10
1